我们是否遗漏了大分割乳腺照射相关的急性毒性?一项大型多中心队列研究报告
该研究前瞻性比较了大分割全乳照射(HF-WBI)患者术后4周随访(2013年1月1日至2015年8月31日,827例)与2周随访(2016年1月1日至2018年8月31日,1862例)的急性毒性检出情况,共分析2689例接受肿块切除术后放疗加补量的患者。总体急性复合毒性在4周随访队列为26.4%,在2周随访队列为27.7%,未校正分析中各急性毒性指标在随访队列间统计学相似。多因素校正模型显示总体急性复合毒性在随访队列间仍相似,且与患者年龄、体重指数、吸烟状态和治疗技术(调强放疗 vs 三维适形放疗)显著相关,但与随访队列无关。结论认为,HF-WBI患者治疗后2周随访较4周随访并未发现急性毒性发生率显著增加。
要点
- 2周随访队列1862例与4周随访队列827例的总体急性复合毒性分别为27.7%和26.4%,未校正及多因素校正后均相似。
- 急性复合毒性与患者年龄、体重指数、吸烟状态及治疗技术(调强放疗 vs 三维适形放疗)显著相关,与随访队列无关。
- HF-WBI患者治疗后2周随访较4周随访未发现急性毒性发生率显著增加。
核心结论
- HF-WBI患者治疗后2周随访较4周随访未发现急性毒性发生率显著增加。
- 该研究为医生和患者提供了HF-WBI用于早期乳腺癌的安全性和耐受性的额外数据。
研究设计与样本
- 前瞻性比较2013年1月1日至2015年8月31日接受HF-WBI的4周随访队列与2016年1月1日至2018年8月31日接受HF-WBI的2周随访队列的急性毒性。
- 共分析2689例接受肿块切除术后放疗加补量的患者,其中2周随访队列1862例,4周随访队列827例。
- 分析采用多因素模型校正其他已知与毒性相关的因素。
- 急性毒性前瞻性定义为放疗完成前7天至完成后42天报告的最大乳腺疼痛(中度或重度评级)和/或湿性脱屑的发生。
主要发现
- 未校正分析中,所有评估的急性毒性指标在随访队列间统计学相似。
- 总体急性复合毒性在4周随访队列为26.4%,在2周随访队列为27.7%。
- 多因素校正模型中总体急性复合毒性在随访队列间仍相似,且与患者年龄、体重指数、吸烟状态和治疗技术(调强放疗 vs 三维适形放疗)显著相关,但与随访队列无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The efficacy and long-term safety of hypofractionated whole breast irradiation (HF-WBI) have been established through multiple randomized trials, yet data about acute toxicities remain more limited. Since 2013, our group has prospectively collected acute toxicity data from weekly treatment evaluations and additional assessment after completion. In 2016, we intentionally shifted the posttreatment assessment follow-up visit from 1 month to 2 weeks to evaluate for missed acute toxicity occurring in that immediate posttreatment window. Here, we report whether 2-week follow-up has resulted in increased detection of acute toxicities compared with 4-week follow-up. METHODS AND MATERIALS: We prospectively compared acute toxicity for patients treated with HF-WBI between January 1, 2013, and August 31, 2015 (4 week follow-up cohort) to patients treated between January 1, 2016, and August 31, 2018 (2 week follow-up cohort). Analyses included a multivariable model that adjusted for other factors known to correlate with toxicity. We prospectively defined acute toxicity as maximum breast pain (moderate or severe rating) and/or occurrence of moist desquamation reported 7 days before the completion of radiation therapy (RT) until 42 days after completion. RESULTS: A total of 2689 patients who received postlumpectomy radiation and boost were analyzed; 1862 patients in the 2-week follow-up cohort and 827 in the 4-week follow-up cohort. All acute toxicity measures assessed were statistically similar between follow-up cohorts when compared in an unadjusted fashion. Overall acute composite toxicity was 26.4% and 27.7% for patients in the 4-week follow-up and 2-week follow-up cohorts, respectively. Overall acute composite toxicity remained similar between follow-up cohorts in a multivariable, adjusted model and was significantly related to patient's age, body mass index, smoking status, and treatment technique (intensity-modulated RT vs 3-dimensional conformal radiation therapy) but not follow-up cohort. CONCLUSIONS: An earlier posttreatment follow-up for HF-WBI patients did not reveal a significant increased incidence of acute toxicities at 2 weeks compared with 4 weeks. This study provides physicians and patients with additional data on the safety and tolerability of HF-WBI for early stage breast cancer.
引用
- Beydoun H, Griffith KA, Jagsi R, et al. Are We Missing Acute Toxicities Associated With Hypofractionated Breast Irradiation? A Report From a Large Multicenter Cohort Study. Int J Radiat Oncol Biol Phys. 2024. PMID: 38364950. doi:10.1016/j.ijrobp.2024.01.225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。